S Di Giambenedetto
Overview
Explore the profile of S Di Giambenedetto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
483
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Iannone V, Lombardi F, Ciccullo A, Lamanna F, Salvo P, Sanfilippo A, et al.
AIDS Behav
. 2025 Jan;
PMID: 39779624
The new Cabotegravir + Rilpivirine long acting (CAB + RPV) is the injectable regimen for treatment-experienced people with HIV (PWH). Little data from real-world settings are available, particularly in more...
2.
Passerotto R, Lamanna F, Salvo P, Iannone V, Steiner R, Carbone A, et al.
Antivir Ther
. 2024 Dec;
29(6):13596535241306467.
PMID: 39698926
Introduction: BIC/FTC/TAF showed efficacy and tolerability in randomized trials as a switch strategy in virologically-suppressed people living with HIV. We evaluated its effectiveness in a real-life setting. Methods: A retrospective...
3.
Katlama C, Bisshop F, Bogner J, Perez Elias M, Di Giambenedetto S, Clarke E, et al.
HIV Med
. 2024 May;
25(7):873-884.
PMID: 38760011
Objectives: Women represent >50% of people with HIV globally but have historically been underrepresented in clinical trials. We evaluated the efficacy and safety of switching to dolutegravir/lamivudine (DTG/3TC) vs continuing...
4.
Ciccullo A, Baldin G, Borghi V, Cossu M, Giacomelli A, Lagi F, et al.
J Antimicrob Chemother
. 2022 Oct;
78(1):117-121.
PMID: 36272137
Objectives: We aimed to investigate and compare the efficacy and safety of two dolutegravir-based two-drug regimens: dolutegravir + lamivudine versus dolutegravir + rilpivirine. Methods: We analysed a cohort of people...
5.
Borghetti A, Alkhatib M, Dusina A, Duca L, Borghi V, Zazzi M, et al.
J Antimicrob Chemother
. 2021 Dec;
77(3):740-746.
PMID: 34849981
Objectives: To compare the efficacy of dolutegravir plus lamivudine dual therapy (DT) with that of dolutegravir plus two NRTIs triple therapy (TT) as switch strategies. Methods: A multicentre cohort of...
6.
Agnes A, Biondi A, Belia F, Di Giambenedetto S, Addolorato G, Antonelli M, et al.
Eur Rev Med Pharmacol Sci
. 2021 Jan;
25(1):480-486.
PMID: 33506939
Objective: The purpose of this paper is to contextualize the case of a patient with a synchronous diagnosis of colorectal cancer (CRC) and endocarditis from S. gallolyticus subsp. pasteuranus (former...
7.
Borghetti A, Ciccullo A, Lombardi F, Baldin G, Belmonti S, Prosperi M, et al.
HIV Med
. 2020 Sep;
22(1):22-27.
PMID: 32964671
Objectives: Nucleoside reverse transcriptase inhibitor (NRTI) transmitted drug resistance mutations (TDRMs) could increase the risk of virological failure (VF) of first-line integrase strand transfer inhibitor (InSTI)-based regimens. Methods: Patients starting...
8.
Ciccullo A, Borghetti A, Dusina A, Segala F, Visconti E, Tamburrini E, et al.
HIV Med
. 2020 Sep;
22(1):e3-e4.
PMID: 32876390
No abstract available.
9.
Tosoni A, Rizzatti G, Nicolotti N, Di Giambenedetto S, Addolorato G, Franceschi F, et al.
Eur Rev Med Pharmacol Sci
. 2020 Aug;
24(15):8202-8209.
PMID: 32767350
Objective: The recent outbreak of SARS-CoV-2 infection in Italy has resulted in a sudden and massive flow of patients into emergency rooms, and a high number of hospitalizations with the...
10.
Borghetti A, Ciccullo A, Paratore M, Rovedi F, Stella L, Marchetti A, et al.
J Infect
. 2020 May;
82(1):159-198.
PMID: 32473233
No abstract available.